Concurrent Doxorubicin Plus Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197

PURPOSE: The combination of doxorubicin and cyclophosphamide (AC) is a standard adjuvant regimen. Doxorubicin and docetaxel (AT) is one of the most active cytotoxic regimens for metastatic breast cancer. The purpose of this trial was to determine whether adjuvant AT improved disease-free survival co...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Goldstein, Lori J., O'Neill, Anne, Sparano, Joseph A., Perez, Edith A., Shulman, Lawrence N., Martino, Silvana, Davidson, Nancy E.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2008
Témata:
Breast Cancer
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2654376/
https://ncbi.nlm.nih.gov/pubmed/18678836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.16.7841
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky